Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)

• Status: Terminated
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To test the therapeutic ratio of accelerated radiotherapy and/or chemotherapy on locally advanced nasopharyngeal carcinoma.

• Phase: N/A

Details

• Lead Sponsor: Hospital Authority, Hong Kong
• Collaborator: The Hong Kong Nasopharyngeal Cancer Study Group
• Treatments: Fluorouracil

Criteria

Inclusion Criteria:

• Undifferentiated or non-keratinizing carcinoma

• Tumor staged as T3-4 AND N0-1

• No evidence of distant metastasis (M0)

• Performance status: 0-2

• Marrow: WBC >= 4 and platelet = 100

• Renal: creatinine clearance = 60

• Informed consent

Exclusion Criteria:

• WHO type I squamous cell carcinoma or adenocarcinoma

• Age >= 70

• Palliative intent or tumor extent mandating AP opposing facio-cervical fields

• Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years

• Previous radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume

• Previous chemotherapy

• Patient is pregnant or lactating